Hilda A. Pickett

Westmead, NSW, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 77 publications

MUTYH activity maintains telomere stability in response to chronic telomeric 8-oxoguanine damage in cancer cells.

MUTYH activity maintains telomere stability in response to chronic telomeric 8-oxoguanine damage in cancer cells.

Journal: bioRxiv : the preprint server for biology

Published: August 20, 2026

Telomere heterochromatin-mediated compartmentalization: Where ALT begins.

Telomere heterochromatin-mediated compartmentalization: Where ALT begins.

Journal: Trends in cell biology

Published: April 21, 2026

Correction: Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy.

Correction: Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 11, 2026

Telomeres and Telomerase.

Telomeres and Telomerase.

Journal: Cold Spring Harbor perspectives in biology

Published: February 09, 2026

Potent synthetic lethality between PLK1 and EYA family inhibitors in tumors of the central and peripheral nervous systems.

Potent synthetic lethality between PLK1 and EYA family inhibitors in tumors of the central and peripheral nervous systems.

Journal: Genes & development

Published: August 19, 2025

Aging-dependent immunological changes in multiple sclerosis.

Aging-dependent immunological changes in multiple sclerosis.

Journal: Frontiers in immunology

Published: July 10, 2025

Potent Cyclic Peptide Inhibitors Disrupt the FANCM-RMI Interaction.

Potent Cyclic Peptide Inhibitors Disrupt the FANCM-RMI Interaction.

Journal: Journal of medicinal chemistry

Published: June 06, 2025

Therapeutic Opportunities for Alternative Lengthening of Telomeres (ALT) Cancers.

Therapeutic Opportunities for Alternative Lengthening of Telomeres (ALT) Cancers.

Journal: Cold Spring Harbor perspectives in biology

Published: April 10, 2025

High-dose vitamin D supplementation and prostate cancer progression: a phase II randomised trial in localised prostate cancer cases with intermediate risk of progression (ProsD).

High-dose vitamin D supplementation and prostate cancer progression: a phase II randomised trial in localised prostate cancer cases with intermediate risk of progression (ProsD).

Journal: British journal of cancer

Published: April 04, 2025

DNA methylation and telomere length in 2-5 year olds with intrauterine preeclampsia exposure: a P4 sub-study.

DNA methylation and telomere length in 2-5 year olds with intrauterine preeclampsia exposure: a P4 sub-study.

Journal: Clinical epigenetics

Published: March 03, 2025

Mechanism of structure-specific DNA binding by the FANCM branchpoint translocase.

Mechanism of structure-specific DNA binding by the FANCM branchpoint translocase.

Journal: Nucleic acids research

Published: May 28, 2024

NONO, SFPQ, and PSPC1 promote telomerase recruitment to the telomere.

NONO, SFPQ, and PSPC1 promote telomerase recruitment to the telomere.

Journal: Nature communications

Published: May 20, 2024

Showing 1-12 of 77

Last Updated: 09/26/2026